Medioint Lifescience Profile
Key Indicators
- Authorised Capital ₹ 2.00 Cr
as on 28-10-2024
- Paid Up Capital ₹ 2.00 Cr
as on 28-10-2024
- Company Age 4 Year, 4 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 7.06 Cr
as on 28-10-2024
- Revenue 391833.23%
(FY 2023)
- Profit -8543.86%
(FY 2023)
- Net Worth 5.90%
(FY 2023)
- Total Assets 74.96%
(FY 2023)
About Medioint Lifescience
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 2.00 Cr and a paid-up capital of Rs 2.00 Cr.
The company currently has active open charges totaling ₹7.06 Cr.
Attaullah Ansari, Mukesh Joshi, Arvindkumar Saroj, and One other member serve as directors at the Company.
- CIN/LLPIN
U24230MP2020PTC052158
- Company No.
052158
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
03 Aug 2020
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Gwalior
Industry
Company Details
- Location
Dhar, Madhya Pradesh, India
- Telephone
- Email Address
- Website
- Social Media
Who are the key members and board of directors at Medioint Lifescience?
Board Members(4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Mukesh Joshi  | Director | 03-Aug-2020 | Current |
| Attaullah Ansari | Director | 08-Jun-2022 | Current |
| Arvindkumar Saroj | Director | 03-Aug-2020 | Current |
| Satish Pawar | Director | 03-Aug-2020 | Current |
Financial Performance of Medioint Lifescience.
Medioint Lifescience Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 391833.23% increase. The company also saw a substantial fall in profitability, with a 8543.86% decrease in profit. The company's net worth moved up by a moderate rise of 5.9%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
What is the Ownership and Shareholding Structure of Medioint Lifescience?
In 2023, Medioint Lifescience had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 11 Aug 2023 | ₹3.00 M | Open |
Others Creation Date: 24 Feb 2023 | ₹1.76 Cr | Open |
Others Creation Date: 29 Oct 2021 | ₹1.50 Cr | Open |
How Many Employees Work at Medioint Lifescience?
Medioint Lifescience has a workforce of 17 employees as of Apr 09, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Medioint Lifescience, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Medioint Lifescience's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
